• Price (EUR)9.20
  • Today's Change-0.04 / -0.43%
  • Shares traded136.70k
  • 1 Year change-16.67%
  • Beta0.4415
Data delayed at least 15 minutes, as of Feb 07 2023 16:35 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.

  • Revenue in EUR (TTM)843.74m
  • Net income in EUR18.72m
  • Incorporated--
  • Employees1.79k
  • Location
    Almirall SARonda General Mitre, 151BARCELONA 08022SpainESP
  • Phone+34 932913000
  • Fax+34 932913681
  • Websitehttps://www.almirall.es/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ALM:MCE since
DFT El Global SL-Physiorelax PortfolioDeal completed03 Feb 202303 Feb 2023Deal completed0.22%--
Data delayed at least 15 minutes, as of Feb 07 2023 16:35 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
FAES Farma SA436.76m85.99m1.08bn1.66k12.62--10.342.480.27660.27661.38--------262,951.20--12.75--15.0763.3363.5119.7218.09--------4.8211.7614.6217.8437.7518.23
Pharma Mar SA227.29m86.13m1.14bn477.0012.995.2812.445.014.774.5212.5811.750.62550.78618.24476,496.8023.7016.0431.0124.7094.4691.1837.8920.582.72--0.1612---14.874.90-32.35--5.07--
Cosmo Pharmaceuticals NV78.15m35.28m1.17bn292.0035.252.3624.1614.941.881.884.3328.120.11772.923.81268,444.205.32-2.095.51-2.1653.4359.6445.17-19.0510.81--0.268--6.77-0.7776374.292.30-14.33--
Eckert & Zieglr Strahln und Mdzntchnk AG213.44m28.61m1.19bn945.0040.815.8430.715.551.371.3710.239.590.59512.446.11246,463.008.118.389.6010.1349.6747.8413.6212.772.3453.280.184835.572.445.5262.2027.0840.1724.82
Camurus AB76.38m2.50m1.20bn170.00514.6414.17335.4515.750.48150.481515.5517.490.76430.93196.595,885,939.002.50-27.663.09-33.8288.1386.733.27-84.903.0347.330.0253--78.7439.4945.93--1.59--
Formycon AG38.98m76.73m1.21bn178.0012.963.0415.5031.,935.7017.17-6.5917.81-7.3931.9729.53197.04-8.862.12--0.0456--20.3516.22-127.42---2.05--
AddLife AB796.47m42.09m1.31bn2.20k32.073.1012.361.643.943.9474.5940.780.76813.996.57--
Zealand Pharma A/S13.51m-131.07m1.43bn203.00--26.03--105.87-22.13-25.892.277.910.07310.10021.76283,371.80-70.93-27.88-88.11-32.4994.20---970.30-275.483.69--0.575---69.28-14.0110.84--53.47--
Euroapi SAS943.90m2.00m1.46bn3.34k976.661.3118.161.550.01590.015910.3011.83------282,435.70--------16.44--0.2225--1.0511.330.0363---5.48---150.79------
Biotest AG505.00m-70.89m1.51bn2.07k--2.46--2.99-3.58-3.5825.5217.380.4561.503.58256,736.10-6.25-2.44-6.92-2.8315.7427.69-13.70-5.862.09-5.090.6138--6.484.79-101.96---32.84--
Almirall SA843.74m18.72m1.68bn1.79k89.851.2339.541.990.10280.10284.607.520.3721.466.30472,417.100.8255-0.73840.9264-0.864578.1877.532.22-2.241.715.610.2104--2.451.59-155.01---2.82--
BioArctic AB20.02m-980.24k1.98bn56.00--34.306,525.7698.73-0.14-0.142.598.920.26-------1.274.90-1.415.9685.5488.98-4.9020.66----0.012640.83886.3110.1690.67------
Dermapharm Holding SE1.01bn175.99m2.09bn2.57k11.864.,346.8012.5312.3714.4914.4664.4157.2117.3715.121.2641.220.5435--18.7816.23144.2065.6128.08--
Genus plc664.56m45.80m2.12bn3.33k46.233.2825.043.190.62350.62359.048.800.635--5.04178,466.203.933.234.643.80----
Laboratorios Farmaceuticos ROVI SA760.67m175.64m2.15bn1.85k11.894.6311.082.833.363.3614.408.611.041.165.86434,422.0024.1012.5633.8316.2760.7658.3123.0914.220.9743123.810.142433.0454.4619.59150.7142.4617.7639.18
Bavarian Nordic A/S322.85m-80.47m2.19bn917.00--2.34--6.79-8.68-8.6836.3098.470.21462.614.963,167,704.00-5.35-2.42-6.74-2.9337.8545.79-24.92-11.371.71-1.640.3719--2.4613.52-267.47--63.17--
Data as of Feb 07 2023. Currency figures normalised to Almirall SA's reporting currency: Euro EUR

Institutional shareholders

12.95%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 17 Nov 20219.08m5.00%
Caixabank Asset Management SGIIC SAas of 30 Sep 20223.34m1.84%
The Vanguard Group, Inc.as of 05 Jan 20232.01m1.11%
Artisan Partners LPas of 30 Jun 20222.00m1.10%
Degroof Petercam Asset Management SAas of 30 Sep 20221.41m0.78%
Wellington Management International Ltd.as of 30 Dec 20221.30m0.72%
Bessemer Investment Management LLCas of 31 Oct 20221.25m0.69%
Norges Bank Investment Managementas of 31 Dec 20211.20m0.66%
Dimensional Fund Advisors LPas of 05 Jan 2023975.01k0.54%
BlackRock Fund Advisorsas of 05 Jan 2023935.66k0.52%
More ▼
Data from 31 Dec 2021 - 30 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.